mAbxience S.L.
http://www.mabxience.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From mAbxience S.L.
Teva And mAbxience Join Forces On Unnamed Oncology Biosimilar
Teva continues to find comfort with an ally on biosimilar development, striking a deal with the Fresenius-Kabi-backed mAbxience for an undisclosed oncology biosimilar.
Intas And mAbxience Strike Global Etanercept Deal
Intas and mAbxience have announced an exclusive licensing agreement covering mAbxience’s etanercept biosimilar candidate in more than 150 countries worldwide, including Europe and the US.
Turkey’s Abdi İbrahim Allies With mAbxience For ‘Unprecedented’ Technology Transfer
Five years after striking a biosimilars alliance with Iceland’s Alvotech, Turkish firm Abdi İbrahim – which boasts the country’s “largest biotech pharmaceutical manufacturing facility” – has shaken hands with Spanish developer mAbxience for technology transfer of an undisclosed oncology biosimilar.
Another Denosumab Deal For mAbxience In MEA
A further licensing deal for biosimilar denosumab has been struck by mAbxience, with MS Pharma set to register and market the Prolia/Xgeva rival in “select MEA markets.”
Company Information
- Industry
- Services
- Contract Manufacturing Organization
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- CHEMO Group
- Kevilmare Holding GmbH
- Insud Pharma
- mAbxience S.A
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice